LSD

• 1. Introduction

  ›

  LSD, lysergic acid diethylamide, does its work in quantities smaller than a grain of sand. A dose as tiny as 20 micrograms, roughly one two-hundredth the mass of a single grain of sand, is enough to alter perception, dissolve the boundary between self and world, and produce effects lasting up to twelve hours. That extraordinary potency explains almost everything that follows in its story: how a laboratory accident in 1943 became a cultural earthquake, how governments purchased it by the kilogram to weaponize it, how musicians and philosophers credited it with transforming their lives, and why it remains one of the most studied and most legally restricted substances on earth. Who first made it, and what happened when he did? How does something measured in millionths of a gram reshape consciousness so profoundly? And after decades of prohibition, why are researchers in 2024 calling it a breakthrough therapy? Those are the questions this documentary sets out to answer.

• 2. The Chemist and the Accident

  ›

  On the 16th of November 1938, Swiss chemist Albert Hofmann synthesized a new compound at Sandoz Laboratories in Basel, Switzerland. He was working through a large program of ergot alkaloid derivatives, searching for medically useful substances, and the molecule he produced that day was the 25th in a series of lysergamides. He set it aside without fanfare. It would be five years before he touched it again.

  On the 19th of April 1943, Hofmann became the first person to intentionally ingest LSD, swallowing 250 micrograms after an earlier accidental exposure had produced strange effects he could not explain. He had chosen the dose by analogy with other ergot compounds, expecting it to be modest. Instead he found the effects far more powerful than anything he had anticipated. That first deliberate self-experiment, now commemorated in psychedelic culture as Bicycle Day, produced a journey that was both overwhelming and revelatory.

  Hofmann reported the synthesis and its effects in the scientific literature alongside his colleague, psychiatrist Werner Stoll, in 1943. Stoll later published a fuller account of LSD's hallucinogenic effects in 1947, the same year Sandoz Laboratories introduced the drug commercially under the trademark name Delysid, marketing it as a psychiatric panacea that could treat everything from schizophrenia to alcoholism. Hofmann would go on to write a memoir titled LSD, My Problem Child, which documented meetings with the German writer Ernst Jünger, with whom he took LSD on several occasions.

• 3. How LSD Works in the Brain

  ›

  At the receptor level, LSD binds with high affinity to most of the serotonin receptors in the human brain, especially the serotonin 5-HT2A receptor. It is this activation of 5-HT2A receptors that researchers attribute the drug's psychedelic effects to. What makes LSD unusual among serotonergic psychedelics is that it also shows significant affinity for dopamine receptors, a trait that appears to generate two pharmacologically distinct phases during a single experience.

  The first phase, driven by serotonin 5-HT2A receptor activity, is characterized by what researchers have described as a sense of "meaningfulness and portentousness." The second phase, emerging roughly four to six hours after administration, is associated with dopamine D2-like receptor activity and is described plainly as a paranoid state. Researcher Daniel X. Freedman and pharmacologist David E. Nichols are among those who have documented and written about this two-phase structure, which has no parallel among simpler psychedelics like the phenethylamines or tryptamines.

  Neuroimaging studies show that LSD reduces the thalamus's ability to filter incoming sensory information before it reaches the cortex. It also decreases activity within the default mode network and flattens the brain's normal hierarchical organization of large-scale activity. Only about one to one and a half percent of a dose actually crosses into the brain; following a typical 100 microgram dose, that means roughly one microgram is distributed into neural tissue, yet levels in the anterior pituitary gland can run ten times higher than in blood.

  One key to the drug's remarkable duration is structural. A crystal structure of the serotonin 5-HT2B receptor bound to LSD revealed that an extracellular loop forms a lid over the binding cavity, trapping the molecule inside. This explains why LSD remains active for hours even though its plasma half-life is roughly three to four hours, with a terminal half-life of about nine hours. In rodents, LSD levels are undetectable in the brain eight hours after dosing, yet the drug still produces measurable effects at that point.

• 4. The Experience Itself

  ›

  Users describe the primary effects of LSD as visual pseudo-hallucinations and altered thought, commonly called a trip. These are termed pseudohallucinations specifically because the patterns and distortions perceived are not experienced as existing in three-dimensional space outside the body. Colors intensify, objects appear to morph or ripple, and geometric patterns emerge on flat surfaces. Sounds distort into echo-like forms, and music takes on an intensified, sometimes overwhelming quality. At high doses, synesthesia, the mixing of sensory channels, can occur alongside temporary dissociation.

  Positive experiences bring feelings of joy, euphoria, heightened appreciation for life, and a sense of interconnectedness that users have compared to spiritual enlightenment. Negative experiences, known as bad trips, bring fear, panic, and paranoia. Whether an experience tilts positive or negative is not fully predictable, but the factors of mood, environment, hydration, sleep, and social setting, collectively known as "set and setting," are considered important in shaping the outcome.

  An afterglow of improved mood can persist for days or weeks after a single use. LSD is not considered addictive; attempts to train laboratory animals to self-administer it have repeatedly failed. Tolerance develops within 24 hours of a dose and typically resets to baseline after three to four days of abstinence. Cross-tolerance occurs between LSD, mescaline, and psilocybin, meaning someone tolerant to one will be partially tolerant to the others. The drug shows significant cross-tolerance with DMT in highly tolerant users as well.

  A 2010 study by David Nutt ranked LSD as significantly less harmful than alcohol when comparing 20 different drugs by their overall harm. At typical recreational doses of 50 to 200 micrograms, no toxicity-related deaths from LSD itself have been recorded despite many millions of exposures. The estimated lethal dose in humans, extrapolated from animal data and case reports, is approximately 100 milligrams, about 1,000 times a typical recreational dose.

• 5. Government Programs and Cold War Use

  ›

  Beginning in the 1950s, the CIA launched a covert research program known as Project MKUltra. The agency purchased the entire world supply of LSD for $240,000 and distributed it through front organizations to American hospitals, clinics, prisons, and research centers. Experiments were conducted on CIA employees, military personnel, doctors, prostitutes, mentally ill patients, and members of the public, typically without the subjects' knowledge or consent. The most well-known of these operations was called Operation Midnight Climax.

  The full scope of MKUltra remains largely unknown. In 1973, acting CIA director Richard Helms destroyed many of the program's key documents. The existence of the program was revealed in the 1975 Rockefeller Commission report to Congress. Declassified documents suggest the CIA may also have spread LSD among civilians in Europe during the 1950s.

  The U.S. Army Chemical Corps conducted parallel experiments through the Edgewood Arsenal human experiments, evaluating LSD alongside other psychoactive substances as potential non-lethal incapacitants. Both programs reflected a belief that a drug capable of dissolving ordinary cognition might be weaponized, a belief that research ultimately failed to sustain. By the time these programs surfaced publicly, LSD had already become something quite different: the defining substance of a generation's counterculture.

• 6. Counterculture, Art, and Music

  ›

  Owsley Stanley established the first major underground LSD factory and, in the mid-1960s, distributed the drug at a standard concentration of 270 micrograms per dose. He became the most important black-market LSD manufacturer in the United States and a central figure in the San Francisco scene that formed around the drug. The Merry Pranksters, organized by novelist Ken Kesey, staged events called Acid Tests in San Francisco, combining LSD use with light shows and improvised music. Tom Wolfe later documented their activities, including a cross-country journey in a psychedelically decorated bus, in The Electric Kool-Aid Acid Test, published in 1968.

  In January 1966, brothers Ron and Jay Thelin opened the Psychedelic Shop in San Francisco's Haight-Ashbury neighborhood, aimed at promoting the safe use of LSD. That October, they organized the Love Pageant Rally in Golden Gate Park to protest California's ban on the drug. The neighborhood became the acknowledged center of the hippie counterculture.

  In London, British academic Michael Hollingshead first tried LSD in America in 1961 after encounters with Aldous Huxley and Timothy Leary, and in 1965 he founded the World Psychedelic Center in Chelsea. He is credited with introducing LSD to musicians including Donovan, Keith Richards, and members of the Beatles. Poster artists Rick Griffin, Victor Moscoso, and Wes Wilson in San Francisco gave the era its visual language. Bands such as the Beatles, the Rolling Stones, the Grateful Dead, Jefferson Airplane, and the Moody Blues used the drug widely. The Beatles' Sgt. Pepper's Lonely Hearts Club Band and Cream's Disraeli Gears were among the works that carried the psychedelic aesthetic into mass culture. Psychedelic music of the 1960s drew on sitars, tablas, backward tape, and studio panning and phasing to replicate the LSD experience in sound.

  In 1966, Timothy Leary formalized LSD's spiritual dimension by founding the League for Spiritual Discovery, with LSD as its sacrament. The drug was already being described by psychiatrist Stanislav Grof as capable of producing religious and mystical experiences that parallel descriptions in the sacred scriptures of major world religions.

• 7. Prohibition and the Long Road Back

  ›

  On the 24th of October 1968, possession of LSD was made illegal in the United States. Two years later, the Controlled Substances Act of 1970 classified it as a Schedule I substance, meaning the law considered it to have a high potential for abuse, no legitimate medical use, and to be unsafe even under medical supervision. The United Nations followed in 1971, listing it as a Schedule I controlled substance under the Convention on Psychotropic Substances, binding most of the world to prohibition. The last FDA-approved study of LSD in patients ended in 1980.

  Legally sanctioned psychiatric use of LSD continued in Switzerland until 1993. In November 2020, Oregon became the first U.S. state to decriminalize possession of small amounts of LSD after voters approved Ballot Measure 110, with the decriminalization taking effect in February 2021. Switzerland today maintains a special authorization program allowing limited medical use for patients with serious, treatment-resistant conditions under physician supervision.

  As of 2017, approximately 10% of people in the United States had used LSD at some point in their lives, with 0.7% having used it in the past year. Adult use increased by 56.4% between 2015 and 2018. Research into LSD's medical potential, which had largely collapsed by the 1960s under the weight of cultural controversy, began a sustained revival after 2009. In 2024, the U.S. Food and Drug Administration designated LSD, under the code names MM120 and DT120, as a breakthrough therapy for generalized anxiety disorder. That designation, the most formal signal of therapeutic promise the FDA can offer before full approval, represents the furthest the drug has traveled toward clinical legitimacy since Sandoz first shipped it to researchers more than seven decades earlier.